# To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

> **NCT07629583** · PHASE1 · RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 46 (estimated)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Cevostamab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT07629583
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-31
- **Primary completion:** 2030-03-29
- **Final completion:** 2030-03-29
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629583, "To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07629583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*